Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool September 11, 2007 Brian Lawler	Where Momenta Stands Momenta Pharmaceuticals updates investors as to the status of drugs in its pipeline. Until the FDA makes up its mind on its lead drug, an anticoagulant, it's anyone's guess as to what the value of the pipeline is. Investors should take note.
The Motley Fool August 12, 2010 Charly Travers	Impax Laboratories' Magic Formula With an earnings yield of 46.6% and a ROA greater than 25%, Impax Laboratories meets the criteria of the screen and would be suitable for purchase by an investor following this mechanical strategy.
The Motley Fool August 11, 2010 Charly Travers	Perfect World's Magic Formula Perfect World meets the criteria of the screen as does Changyou.com with its 15% yield and sky high ROA. Both of those companies would be suitable for purchase by an investor following this mechanical strategy.
The Motley Fool August 23, 2010 Charly Travers	Lorillard's Magic Formula A simple and proven method for market-beating returns.
The Motley Fool January 20, 2011 Jim Royal	Big Pharma's Magic Formula Joel Greenblatt's Magic Formula revolves around two factors: How cheap is the stock? How profitable is the company? Let's see how some Big Pharma companies fare.
The Motley Fool August 12, 2010 Charly Travers	Agilent's Magic Formula With an earnings yield of 59.9% and a ROA greater than 25%, Agilent Technologies meets the criteria of the screen and would be suitable for purchase by an investor following this mechanical strategy.
The Motley Fool August 16, 2010 Charly Travers	Bridgepoint Education's Magic Formula With an earnings yield of 34.1% and a ROA of 37.2%, Bridgepoint Education blows the screen criteria out of the water
The Motley Fool January 21, 2011 Jim Royal	Trucking's Magic Formula This mechanical strategy could be magic.
The Motley Fool August 10, 2010 Charly Travers	Coach's Magic Formula With an earnings yield of 10.3% and a return on assets greater than 25%, Coach meets the criteria of this mechanical strategy screen.
The Motley Fool January 20, 2011 Jim Royal	Big Tobacco's Magic Formula Joel Greenblatt's Magic Formula revolves around two factors: How cheap is the stock? How profitable is the company? Let's see how some tobacco companies fare.
The Motley Fool August 16, 2010 Charly Travers	Renaissance Learning's Magic Formula With an earnings yield of 11.1% and a ROA greater than 25%, Renaissance Learning would be suitable for purchase by an investor.
The Motley Fool August 16, 2010 Charly Travers	Domino's Magic Formula A simple and proven method for market-beating returns.
The Motley Fool August 10, 2010 Charly Travers	Gilead Sciences' Magic Formula A simple screen for market-beating returns.
The Motley Fool August 10, 2010 Charly Travers	PDL BioPharma's Magic Formula If you want low-fuss investing options that aren't mutual funds or exchange-traded funds, you should consider a mechanical investing strategy. See how it works with this BioPharma stock.
The Motley Fool August 16, 2010 Charly Travers	Select Comfort's Magic Formula Select Comfort meets the criteria of the screen and would be suitable for purchase.
The Motley Fool August 12, 2010 Charly Travers	The Buckle's Magic Formula The Magic Formula just might work for this retailer.
The Motley Fool January 21, 2011 Jim Royal	Consumer Goods' Magic Formula This mechanical strategy could be magic.
The Motley Fool November 6, 2006 Brian Lawler	The Impending Verdict on Momenta The drug developer isn't willing to wait for potential legislation on generic drugs. Investors, take note.
The Motley Fool August 10, 2010 Charly Travers	Apollo Group's Magic Formula A simple screen for market-beating returns applied to for-profit education companies.
The Motley Fool January 21, 2011 Jim Royal	Retail's Magic Formula Joel Greenblatt's Magic Formula revolves around two factors: How cheap is the stock? How profitable is the company? How do these retail companies fare?: Wal-Mart... Costco... Target... TJX...
The Motley Fool January 21, 2011 Jim Royal	Telecom's Magic Formula Joel Greenblatt's Magic Formula revolves around two factors: How cheap is the stock? How profitable is the company? How do these telecom companies fare?: AT&T... Verizon... Vodafone... Sprint Nextel...
The Motley Fool August 11, 2010 Charly Travers	Aeropostale's Magic Formula With an earnings yield of 20.9% and a ROA well above 25%, Aeropostale blows away the criteria of the screen and would be suitable for purchase by an investor following this mechanical strategy.
The Motley Fool August 11, 2010 Charly Travers	Moody's Magic Formula A simple screen for market-beating returns. Value investing is a proven strategy and the first part of the Magic Formula is to screen for stocks that are cheap.
The Motley Fool January 10, 2012 John Rosevear	A Better Idea Than the Dogs of the Dow The "Dogs of the Dow" strategy has had its day -- but its basic idea is sound.
The Motley Fool April 15, 2011 Morgan House	My Guess: Joel Greenblatt Singlehandedly Humbles the Fund Industry Joel Greenblatt, hedge fund manager and author of the wildly popular book, The Little Book That Beats the Market, has a new project. It's a book called The Big Secret for the Small Investor.
The Motley Fool January 17, 2006 Bill Barker	When the "Top 25" Meets the "Top 12" Investors will do well reading Joel Greenblatt's The Little Book That Beats the Market and using his free formula to identify likely market-beating stocks.
The Motley Fool July 28, 2010 Brian Orelli	Fighting Hard to Keep a Blockbuster Sanofi is suing the FDA to take back approval of a competing generic drug. Did you expect something different?
The Motley Fool July 14, 2008 Brian Orelli	Teva Gets a Taste of Its Own Medicine Momenta Pharmaceuticals and Novartis are challenging the patents on Teva Pharmaceutical's blockbuster multiple sclerosis drug Copaxone.
The Motley Fool February 15, 2007 Brian Lawler	A Momenta's Pause The pharmaceutical elaborates on plans for its generic version of blockbuster Lovenox. With so much going on, the rest of 2007 is sure to be a wild ride for Momenta investors.
The Motley Fool December 21, 2005 Bill Mann	Can a Little Book Beat the Market? Hedge-fund manager Joel Greenblatt's newest release, The Little Book That Beats the Market, is a must-read for investors.
The Motley Fool July 23, 2010 Luke Timmerman	Momenta Gets FDA Green Light for Generic Anti-Clotting Drug The FDA says "yes" to Momenta Pharmaceuticals.
The Motley Fool February 14, 2008 Brian Lawler	Sanofi Stagnates French drugmaker Sanofi-Aventis posts fourth-quarter earnings in which its top drugs get some protection, but free cash flow drops.
The Motley Fool January 19, 2007 Karl Thiel	The Best Drug Stock for 2007: Momenta Investors, swing for the fences with this drug company.
The Motley Fool May 9, 2007 Brian Lawler	Where Is Momenta's Momentum? Momenta awaits an FDA regulatory decision and announces quarterly financial results. Investors, take note.
The Motley Fool August 29, 2007 Sham Gad	The Intelligent Investor's Tool Set Using the right search tools is critical to creating a solid investment search strategy. Read on for a few excellent stock screening sites to get you started.
The Motley Fool July 21, 2011 Brian Orelli	Keep an Eye on Biotech Partners' Earnings Novartis' earnings are important for small biotechs Momenta and Vanda.
The Motley Fool October 26, 2011 Brian Orelli	Momenta Stopped. Again. Oh, no - an authorized generic gets launched.
The Motley Fool November 7, 2007 Brian Orelli	Momenta Stopped Momenta and Novartis receive a not-approvable letter for their new drug application on their generic version of Lovenox, due to worries that it might cause an immune reaction. Investors, take note.
The Motley Fool November 2, 2010 Travis Hoium	Momenta Pharmaceuticals Shares Plunged: What You Need to Know Momenta Pharmaceuticals shares fell 10% in trading early Tuesday after Teva Pharmaceutical Industries said it expects FDA approval this year on a drug to compete with Momenta's enoxaparin.
Registered Rep. March 1, 2006 David A. Geracioti	Who Needs 'Ya? Joel Greenblatt's new book, The Little Book That Beats the Market, is a simple value investing treatise that allows retail investors to create a portfolio based on Gotham Capital's own strategy. And guess what the message is? "You can do it yourself."
The Motley Fool June 23, 2006 Mike Norman	It's Just Too Hard The best way to invest can also be the most difficult. Waiting for shares of good companies to become cheap takes patience as well.
The Motley Fool October 31, 2011 Brian Orelli	Spectrum Looking More Investable Spectrum's problem is that it's hard to value the unknown.
The Motley Fool October 31, 2011 Brian Orelli	5 One-Drug Wonders Going for No. 2 Here are five drugmakers hoping not to become one-hit wonders: Vertex... Onyx... Momenta... Elan... Dendreon...
The Motley Fool March 18, 2009 Brian Orelli	Johnson & Johnson and Shakespeare The stage is set for a dramatic decision.
The Motley Fool January 10, 2007 John Reeves	Is Your Stock a Dog? A dividend yield can be a very misleading ratio, and when it comes to identifying stable companies that deliver regular and growing cash flows, you must look deeper than just a single metric.
The Motley Fool May 17, 2011 Jeff Bailey	If You Believe in the U.S. Economy Recovery, Look at Wells Fargo There's a reason Warren Buffett's Berkshire Hathaway owns 6.8% of Wells.
The Motley Fool October 1, 2010 Anders Bylund	This Is Why You Buy on Rumors, Sell on News Apple is not kicking Cirrus out, after all.
The Motley Fool November 24, 2010 Eric Bleeker	Hate to Say I Told You So: Cirrus Soars The audio specialist chip maker pops after my recent Rising Stars buy recommendation.
The Motley Fool April 7, 2010 Anders Bylund	Ode to the Unsung iPad Hero You want to know more about this obscure semiconductor stock before it becomes a very big deal.
The Motley Fool November 27, 2006 Matthew Crews	Aeropostale: Buy or Sell? Should you stay or should you go now? A 20% discount from Aeropostale's current valuation comes as no surprise, and it could create a buying opportunity.